Survival in patients with heart failure and implantable cardioverter-defibrillator in an electrophysiological unit in Pereira, Colombia.
Supervivencia en pacientes con falla cardiaca y desfibrilador automático implantable en una unidad de electrofisiología de Pereira, Colombia Survival in patients with implantable cardioverter-defibrillator and heart failure
Open | Download
Issue
Section
Artículos de Investigación
How to Cite
Sánchez Duque, J. A. ., Arango Franco, R. ., Martínez, J. W., Sosa Urrea, J. D. ., Marín Medina, D. S. ., Orozco Hernández, J. P. ., Martínez Muñoz, M. A. ., & Henao Martínez, J. F. (2021). Survival in patients with heart failure and implantable cardioverter-defibrillator in an electrophysiological unit in Pereira, Colombia.: Survival in patients with implantable cardioverter-defibrillator and heart failure. Archivos De Medicina , 21(1), 35-44. https://doi.org/10.30554/archmed.21.1.3809.2021
Download Citation
Dimensions
How to Cite
Sánchez Duque, J. A. ., Arango Franco, R. ., Martínez, J. W., Sosa Urrea, J. D. ., Marín Medina, D. S. ., Orozco Hernández, J. P. ., Martínez Muñoz, M. A. ., & Henao Martínez, J. F. (2021). Survival in patients with heart failure and implantable cardioverter-defibrillator in an electrophysiological unit in Pereira, Colombia.: Survival in patients with implantable cardioverter-defibrillator and heart failure. Archivos De Medicina , 21(1), 35-44. https://doi.org/10.30554/archmed.21.1.3809.2021
Download Citation
license
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Show authors biography
Introduction: Implantable cardioverter defibrillator therapy seeks to prevent sudden cardiac death by collapsing malignant arrhythmias.
Objective: to identify the clinical variables that impact on the mortality of patients with heart failure implanted with cardioverter defibrillator.
Material y methods: Retrospective cohort study. Patients with a defibrillator implant from the year 2010 to the year 2012 were included, with functional device, clinical history and availability of follow-up until the first quarter of 2014.
Results: A total of 30 patients were included, with a 77% survival at four years of follow-up. 82.7% of the patients presented with ischemic heart disease and the mean left ventricular ejection fraction was 27.8 ± 6.3. The mean time of use of the defibrillator was 2.1 years, the reported mayor danger rate was 6% for days 759 and 760. An association was found between a QRS mayor duration at 120 ms (HR = 7.7, 90% CI = 1.77-33.6, p = 0.022), atrial fibrillation (HR = 4.2, 90% CI = 1.13-15.68, p = 0.072), and beta- blockers (HR = 0.15, 90% CI = 0.03-0.64, p = 0.031) with survival time.
Discussion: The prevention of death is conditioned by pharmacological optimization, as well as structural and electrical conduction anomalies, so the monitoring and adjustment of pharmacological therapy should be increased.
Conclusions: the use of beta-blockers in patients with atrial fibrillation and QRS duration greater than 120 ms is a protective factor.
Article visits 900 | PDF visits 62
Downloads
Download data is not yet available.
- Kamp NJ, Al-Khatib SM. The subcutaneous implantable cardioverter-defibrillator in review. Am Heart J. 2019; 217:131-9. DOI: 10.1016/j.ahj.2019.08.010
- Bob-Manuel T, Jenkins JS, Morin DP. Non-arrhythmic causes of sudden death: A comprehensive review. Prog Cardiovasc Dis. 2019; 62(3):265-71. DOI: 10.1016/j.pcad.2019.05.004
- Wong CX, Brown A, Lau DH, Chugh SS, Albert CM, Kalman JM, et al. Epidemiology of Sudden Cardiac Death: Global and Regional Perspectives. Heart Lung Circ. 2019; 28(1):6-14. DOI: 10.1016/j.hlc.2018.08.026
- Dimos A, Xanthopoulos A, Papamichalis M, Bourazana A, Tavoularis D, Skoularigis J, et al. Sudden Arrhythmic Death at the Higher End of the Heart Failure Spectrum. Angiology. 2020; 71(5):389-96. DOI: 10.1177/0003319719896475
- Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation. 2010;122(13):1265-71. DOI: 10.1161/CIRCULATIONAHA.110.940148
- Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. DOI: 10.1056/NEJMoa043399
- Stavrakis S, Asad Z, Reynolds D. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Electrophysiol. 2017; 28(6):659-65. DOI: 10.1111/jce.13204
- Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335(26):1933-40. DOI: 10.1056/NEJM199612263352601
- Borne RT, Katz D, Betz J, Peterson PN, Masoudi FA. Implantable Cardioverter-Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review. J Am Heart Assoc. 2017; 6(3):e005515. DOI: 10.1161/JAHA.117.005515
- Lévesque V, Laplante L, Shohoudi A, Apers S, Kovacs AH, Luyckx K, et al. Implantable cardioverter-defibrillators and patient-reported outcomes in adults with congenital heart disease: An international study. Heart Rhythm. 2020; 17(5):768-76. DOI: 10.1016/j.hrthm.2019.11.026
- Willy K, Reinke F, Bögeholz N, Ellermann C, Rath B, Köbe J, et al. The role of entirely subcutaneous ICD™ systems in patients with dilated cardiomyopathy. J Cardiol. 2020; 75(5):567-70. DOI: 10.1016/j.jjcc.2019.10.005
- Stolfo D, Albani S, Savarese G, Barbati G, Ramani F, Gigli M, et al. Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis. Int J Cardio. 2020; 307:75-81. DOI: 10.1016/j.ijcard.2020.02.025
- Arango-Franco R, Cárdenas-Castellanos JM, Rivera-Toquica A, Martínez JW, Marín-Medina DS, Orozco-Hernández JP, et al. Terapia de resincronización cardíaca con o sin cardiodesfibrilador versus terapia con desfibrilador automático, Pereira (Colombia): un estudio de cohorte. Iatreia. 2016; 29:133-43. DOI: 10.17533/udea.iatreia.v29n2a03
- Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15(8):1070-118. DOI: 10.1093/europace/eut206
- Exner DV, Birnie DH, Moe G, Thibault B, Philippon F, Healey JS, et al. Canadian Cardiovascular Society guidelines on the use of cardiac resynchronization therapy: evidence and patient selection. Can J Cardiol. 2013; 29(2):182-95. DOI: 10.1016/j.cjca.2012.10.006.
- Gialama F, Prezerakos P, Maniadakis N. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2014;12(1):41-9. DOI: 10.1007/s40258-013-0069-2
- Narbondo F, Pouso J, Varela G, Calleriza F, Do Mato G, Reyes Caorsi W. Cardiodesfibriladores implantables: Diecinueve años de experiencia en un centro de nuestro país. Rev Urug Cardiol. 2013; 28:141-50.
- Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013: 3(1):5-14.
- Arango Franco R, Martínez JW, Cárdenas Castellanos JM, Rivera Toquica AA, Marín Medina DS, Orozco Hernández JP, et al. Falla cardíaca avanzada en pacientes tratados con dispositivos electrofisiológicos en una unidad de electrofisología, Pereira (Colombia). Investigaciones Andina. 2014; 16:978-88. DOI: 10.33132/01248146.76
- Rosso F, Perafán-Bautista PE, Carrillo-Gómez DC, Ramos-Amézquita MH, Cedano-Rincón J. Infección relacionada con los dispositivos cardiovasculares. Rev Col Cardiol. 2016; 23:508-13. DOI: 10.1016/j.rccar.2016.07.005
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27):2129-200. DOI: 10.1093/eurheartj/ehw128
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann intern Med. 2009; 150(9):604-12.
- Cox C, Chu H, Schneider MF, Muñoz A. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med. 2007;26(23):4352-74. DOI: 10.1002/sim.2836
- CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146):9-13. DOI: 10.1016/S0140-6736(98)11181-9
- Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003; 362(9377):7-13. DOI: 10.1016/S0140-6736(03)13800-7
- Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. N Engl J Med. 2001; 344(22):1651-8. DOI: 10.1056/NEJM200105313442201
- Bode-Schnurbus L, Böcker D, Block M, Gradaus R, Heinecke A, Breithardt G, et al. QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. Heart. 2003; 89(10):1157-62. DOI: 10.1136/heart.89.10.1157
- Kashani A, Barold SS. Significance of QRS Complex Duration in Patients With Heart Failure. J Am Coll Cardiol. 2005; 46(12):2183-92. DOI: 10.1016/j.jacc.2005.01.071
- Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T, Ząbek A, et al. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Kardiol Pol. 2012; 70(11):1099-110.
- Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail. 2011; 4(6):740-6. DOI: 10.1161/CIRCHEARTFAILURE.111.962688
- Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015; 36(46):3250-7. DOI: 10.1093/eurheartj/ehv513
- Cadrin-Tourigny J, Shohoudi A, Roy D, Talajic M, Tadros R, Mondésert B, et al. Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. JACC Heart fail. 2017; 5(2):99-106. DOI: 10.1016/j.jchf.2016.10.015
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; 134(13):e282-e93. DOI: 10.1161/CIR.0000000000000435
- Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol. 2002;39(8):1323-8. DOI: 10.1016/s0735-1097(02)01784-9
- Perilla-Orozco DM, Pantoja-Molina AD, Sánchez-Duque JA. Abordaje integral del adulto mayor: Una mirada desde la atención primaria. Aten Fam. 2020;27-(2):109-110. DOI: 10.22201/facmed.14058871p.2020.2.75205
- Sánchez-Duque JA, Blanco-Betancur M, Betancourt-Quevedo R, Issa-Sánchez MA. Cuidados al final de la vida y eutanasia en Colombia. Discover Medicine. 2019;3(1):11-12.
- Pantoja-Molina AD, Perilla-Orozco DM, Sánchez-Duque JA. Prescripción inapropiada en adultos mayores: Una mirada desde la atención primaria. Rev Clin Med Fam. 2020; 13(2): 171-172.
